|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel | Konferenzbeitrag
Anzahl der Publikationen: 129
Zeitschriftenartikel
Wisgalla, Anne 
ORCID: https://orcid.org/0000-0001-8900-0186 und Hasford, Joerg
(2022):
Four reasons why too many informed consents to clinical research are invalid: a critical analysis of current practices.
In: BMJ Open, Bd. 12, Nr. 3, e050543
[PDF, 257kB]
ORCID: https://orcid.org/0000-0001-8900-0186 und Hasford, Joerg
(2022):
Four reasons why too many informed consents to clinical research are invalid: a critical analysis of current practices.
In: BMJ Open, Bd. 12, Nr. 3, e050543
[PDF, 257kB]
Ziegler, Anette-Gabriele; Arnolds, Stefanie; Hasford, Joerg; Kordonouri, Olga; Lundgren, Markus; Oltarzewski, Mariusz; Pekalski, Marcin L.; Pfirrmann, Markus; Snape, Matthew D.; Szypowska, Agnieszka und Todd, John A.
(2021):
Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity. The GPPAD-SINT1A randomised controlled trial protocol.
In: BMJ Open, Bd. 11, Nr. 11, e052449
[PDF, 491kB]
Faust, Alice; Sierawska, Anna; Krueger, Katharina; Wisgalla, Anne; Hasford, Joerg und Strech, Daniel
(2021):
Challenges and proposed solutions in making clinical research on COVID-19 ethical: a status quo analysis across German research ethics committees.
In: Springer Nature Medical Ethics, Bd. 22, Nr. 1, 96
Ziegler, Anette-Gabriele; Arnolds, Stefanie; Kolln, Annika; Achenbach, Peter; Berner, Reinhard; Bonifacio, Ezio; Casteels, Kristina; Elding Larsson, Helena; Gundert, Melanie; Hasford, Joerg; Kordonouri, Olga; Lundgren, Markus; Oltarzewski, Mariusz; Pekalski, Marcin L.; Pfirrmann, Markus; Snape, Matthew D.; Szypowska, Agnieszka und Todd, John A.
(2021):
Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol.
In: BMJ Open, Bd. 11, Nr. 11, e052449
Seiberth, Sarah; Bauer, Dominik; Schönermarck, Ulf; Mannell, Hanna; Stief, Christian; Hasford, Joerg und Strobach, Dorothea
(2020):
Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission.
In: European journal of clinical pharmacology
[PDF, 992kB]
Pfirrmann, Markus; Clark, Richard E.; Prejzner, Witold; Lauseker, Michael; Baccarani, Michele; Saussele, Susanne; Guilhot, François; Hasford, Joerg; Hochhaus, Andreas und Hoffmann, Verena S.
(2020):
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
In: Leukemia, Bd. 34, Nr. 8: S. 2138-2149
[PDF, 969kB]
Lauseker, Michael; Bachl, Katharina; Turkina, Anna; Faber, Edgar; Prejzner, Witold; Olsson-Strömberg, Ulla; Baccarani, Michele; Lomaia, Elza; Zackova, Daniela; Ossenkoppele, Gert; Griskevicius, Laimonas; Schubert-Fritschle, Gabriele; Sacha, Tomasz; Heibl, Sonja; Koskenvesa, Perttu; Bogdanovic, Andrija; Clark, Richard E.; Guilhot, Joelle; Hoffmann, Verena S.; Hasford, Joerg; Hochhaus, Andreas und Pfirrmann, Markus
(November 2019):
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
In: American Journal of Hematology, Bd. 94, Nr. 11: S. 1236-1243
[PDF, 1MB]
Lauseker, Michael; Gerlach, Roman; Worseg, Wenke; Haferlach, Torsten; Tauscher, Martin; Hasford, Joerg und Hoffmann, Verena S.
(Oktober 2019):
Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study.
In: European Journal of Haematology, Bd. 103, Nr. 4: S. 362-369
[PDF, 543kB]
Saussele, Susanne; Hehlmann, Rüdiger; Fabarius, Alice; Jeromin, Sabine; Proetel, Ulrike; Rinaldetti, Sebastien; Kohlbrenner, Katharina; Einsele, Hermann; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Oppliger Leibundgut, Elisabeth; Heim, Dominik; Krause, Stefan W.; Hofmann, Wolf-Karsten; Hasford, Joerg; Pfirrmann, Markus; Müller, Martin C.; Hochhaus, Andreas und Lauseker, Michael
(2018):
Defining therapy goals for major molecular remission in chronic myeloid leukemia: Results of the randomized CML Study IV.
In: Leukemia, Bd. 32, Nr. 5: S. 1222-1228
[PDF, 599kB]
Hummel, Sandra; Beyerlein, Andreas; Pfirrmann, Markus; Hofelich, Anna; Much, Daniela; Hivner, Susanne; Bunk, Melanie; Herbst, Melanie; Peplow, Claudia; Walter, Markus; Kohn, Denise; Hummel, Nadine; Kratzsch, Jürgen; Hasford, Joerg; Ziegler, Anette-G.; Hummel, Michael und Füchtenbusch, Martin
(2018):
Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study.
In: Molecular Metabolism, Bd. 9: S. 168-175
Pfirrmann, Markus; Evtimova, D.; Saussele, S.; Castagnetti, F.; Cervantes, F.; Janssen, Jan; Hoffmann, Verena; Gugliotta, G.; Hehlmann, R.; Hochhaus, A.; Hasford, Joerg und Baccarani, M.
(12. Januar 2017):
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
In: Journal of Cancer Research and Clinical Oncology, Bd. 143, Nr. 5: S. 843-850
Lauseker, Michael; Hasford, Joerg; Saussele, Susanne; Kremers, Stephan; Kraemer, Doris; Lindemann, Walter; Hehlmann, Rüdiger und Pfirrmann, Markus
(2017):
Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.
In: Cancer, Bd. 123, Nr. 13: S. 2467-2471
Hehlmann, Rüdiger; Lauseker, Michael; Saußele, Susanne; Hochhaus, Andreas; Hasford, Joerg; Pfirrmann, Markus; Kolb, Hans-Jochem; Spiekermann, Karsten; Fabarius, Alice; Müller, M. C.; Proetel, Ulrike; Kohlbrenner, K.; Voskanyan, A.; Rinaldetti, S.; Seifarth, W.; Spieß, B.; Krause, S. W.; Neubauer, A.; Burchert, A.; Hossfeld, Dieter K.; Schafhausen, P.; Nerl, C.; Gratwohl, A.; Heim, D.; Baerlocher, Gabriela M.; Brümmendorf, Tim H.; Fuchs, R.; Haferlach, C.; Jeromin, S.; Schlegelberger, Brigitte; Balleisen, L.; Goebeler, M. C.; Hänel, M.; Ho, A.; Dengler, J.; Falge, C.; Kanz, L.; Kremers, S.; Kneba, M.; Stegelmann, F.; Köhne, C. A.; Lindemann, H. W.; Waller, C. F.; Pfreundschuh, Michael; Berdel, Wolfgang E.; Müller, L.; Edinger, M.; Mayer, J.; Beelen, D. W.; Bentz, M.; Link, H.; Hertenstein, Bernd; Wernli, Martin; Schlegel, F.; Schlag, R.; Wit, M. de; Trumper, L.; Hebart, H.; Hahn, M.; Thomalla, J.; Scheid, C.; Verbeek, W.; Eckart, M. J.; Gassmann, W.; Pezzutto, A.; Schenk, M.; Brossart, P.; Geer, T.; Bildat, S. und Schäfer, E.
(2017):
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
In: Leukemia, Bd. 31, Nr. 11: S. 2398-2406
Pfirrmann, Markus; Baccarani, M.; Saußele, Susanne; Guilhot, J.; Cervantes, F.; Ossenkoppele, G.; Hoffmann, V. S.; Castagnetti, F.; Hasford, Joerg; Hehlmann, R. und Simonsson, B.
(2016):
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
In: Leukemia, Bd. 30, Nr. 1: S. 48-56
Lauseker, Michael; Gerlach, R.; Tauscher, M. und Hasford, Joerg
(2016):
Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.
In: Journal of Cancer Research and Clinical Oncology, Bd. 142, Nr. 7: S. 1441-1447
Miranda, M. B.; Lauseker, Michael; Kraus, M. P.; Proetel, U.; Hanfstein, B.; Fabarius, A.; Baerlocher, Gabriela M.; Heim, D.; Hossfeld, D. K.; Kolb, H. J.; Krause, S. W.; Nerl, C.; Brümmendorf, Tim H.; Verbeek, W.; Fauser, A. A.; Prummer, O.; Neben, K.; Hess, U.; Mahlberg, R.; Ploger, C.; Flasshove, M.; Rendenbach, B.; Hofmann, W. K.; Muller, M. C.; Pfirrmann, Markus; Hochhaus, A.; Hasford, Joerg; Hehlmann, R. und Saußele, Susanne
(2016):
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
In: Leukemia, Bd. 30, Nr. 6: S. 1255-1262
Schmiedl, S.; Fischer, R.; Ibanez, L.; Fortuny, J.; Thürmann, P. A.; Ballarin, E.; Ferrer, P.; Sabate, M.; Rottenkolber, D.; Gerlach, R.; Tauscher, M.; Reynolds, R.; Hasford, Joerg und Rottenkolber, Marietta
(2016):
Tiotropium Respimat((R)) vs. HandiHaler((R)): Real-life usage and TIOSPIR trial generalizability.
In: British Journal of Clinical Pharmacology, Bd. 81, Nr. 2: S. 379-388
Afonso, A.; Schmiedl, S.; Becker, C.; Tcherny-Lessenot, S.; Primatesta, P.; Plana, E.; Souverein, P.; Wang, Y.; Korevaar, J. C.; Hasford, Joerg; Reynolds, R.; de Groot, M. C.; Schlienger, R.; Klungel, O. und Rottenkolber, Marietta
(2016):
A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction.
In: European Journal of Clinical Pharmacology, Bd. 72, Nr. 9: S. 1105-1116
Kossak-Roth, U.; Saußele, Susanne; Aul, C.; Büchner, T.; Dohner, H.; Dugas, Martin; Ehninger, G.; Ganser, A.; Giagounidis, A.; Gökbuget, Nicola; Griesshammer, M.; Hasford, Joerg; Heuser, M.; Hiddemann, Wolfgang; Hochhaus, A.; Hoelzer, D.; Niederwieser, D. W.; Reiter, A.; Röllig, C. und Hehlmann, R.
(2016):
Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL).
In: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, Bd. 59, Nr. 4: S. 444-453
Gratwohl, A.; Pfirrmann, Markus; Zander, A.; Kröger, N.; Beelen, D.; Novotny, J.; Nerl, C.; Scheid, C.; Spiekermann, Karsten; Mayer, J.; Sayer, H. G.; Falge, C.; Bunjes, D.; Döhner, H.; Ganser, A.; Schmidt-Wolf, I.; Schwerdtfeger, R.; Baurmann, H.; Kuse, R.; Schmitz, N.; Wehmeier, A.; Fischer, J. T.; Ho, A. D.; Wilhelm, M.; Goebeler, M. E.; Lindemann, H. W.; Bormann, M.; Hertenstein, B.; Schlimok, G.; Baerlocher, Gabriela M.; Aul, C.; Pfreundschuh, M.; Fabian, M.; Staib, P.; Edinger, M.; Schatz, M.; Fauser, A.; Arnold, R.; Kindler, T.; Wulf, G.; Rosselet, A.; Hellmann, A.; Schäfer, E.; Prümmer, O.; Schenk, M.; Hasford, Joerg; Heimpel, H.; Hossfeld, D. K.; Kolb, H.-J.; Büsche, G.; Haferlach, C.; Schnittger, S.; Müller, M. C.; Reiter, A.; Berger, Ute; Saußele, Susanne; Hochhaus, A. und Hehlmann, R.
(2016):
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.
In: Leukemia, Bd. 30, Nr. 3: S. 562-569
Hoffmann, V. S.; Baccarani, M.; Hasford, Joerg; Castagnetti, F.; Raimondo, F. di; Simonsson, B.; Indrak, K.; Sninska, Z.; Sacha, T.; Clark, R.; Bogdanovic, A.; Hellmann, A.; Griskevicius, L.; Schubert-Fritschle, Gabriele; Sertic, D.; Guilhot, J.; Lejniece, S.; Zupan, I.; Burgstaller, S.; Koskenvesa, P.; Everaus, H.; Costeas, P.; Lindörfer, Doris; Rosti, G.; Saussele, S.; Hochhaus, A.; Hehlmann, R.; Turkina, A. und Casado, L. F.
(2016):
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
In: Leukemia, Bd. 31, Nr. 3: S. 593-601
Rottenkolber, Marietta; Fischer, Rainald; Ibáñez, Luisa; Fortuny, Joan; Reynolds, Robert; Amelio, Justyna; Gerlach, Roman; Tauscher, Martin; Thürmann, Petra; Hasford, Joerg und Schmiedl, Sven
(2015):
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial.
In: BMC Pulmonary Medicine
15:55
[PDF, 634kB]
Pfirrmann, Markus; Lauseker, Michael; Hoffmann, V. S. und Hasford, Joerg
(2015):
Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.
In: Annals of Hematology / Supplements, Bd. 94, Nr. 2:
S209-18
Lauseker, Michael; Hasford, Joerg; Hoffmann, V. S.; Mueller, M. C.; Hehlmann, R. und Pfirrmann, Markus
(2015):
A multi-state model approach for prediction in chronic myeloid leukaemia.
In: Annals of Hematology, Bd. 94, Nr. 6: S. 919-927
Lauseker, Michael; Schemenau, J.; Strupp, C.; Kundgen, A.; Gattermann, N.; Hasford, Joerg und Germing, U.
(2015):
In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
In: British Journal of Haematology, Bd. 170, Nr. 5: S. 687-693
Rottenkolber, Marietta; Voogd, E.; van Dijk, L.; Primatesta, P.; Becker, C.; de Groot, M. C.; Plana, E.; Alvarez, Y.; Durand, J.; Slattery, J.; Afonso, A.; Requena, G.; Huerta, C.; Alvarez, A.; de Abajo, F. J.; Tauscher, M.; Hasford, Joerg; Fischer, R.; Reynolds, R. und Schmiedl, S.
(2015):
Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs.
In: Respiratory Medicine, Bd. 109, Nr. 7: S. 828-837
Saußele, Susanne; Krauß, M. P.; Hehlmann, R.; Lauseker, Michael; Proetel, U.; Kalmanti, L.; Hanfstein, B.; Fabarius, A.; Kraemer, D.; Berdel, W. E.; Bentz, M.; Staib, P.; de Wit, M.; Wernli, M.; Zettl, F.; Hebart, H. F.; Hahn, M.; Heymanns, J.; Schmidt-Wolf, I.; Schmitz, N.; Eckart, M. J.; Gassmann, W.; Bartholomäus, A.; Pezzutto, A.; Oppliger Leibundgut, E.; Heim, D.; Krause, S. W.; Burchert, A.; Hofmann, W. K.; Hasford, Joerg; Hochhaus, A.; Pfirrmann, Markus und Müller, M. C.
(2015):
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
In: Blood, Bd. 126, Nr. 1: S. 42-49
Fabarius, A.; Kalmanti, L.; Dietz, C. T.; Lauseker, Michael; Rinaldetti, S.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Jotterand, M.; Hanfstein, B.; Seifarth, W.; Hänel, M.; Köhne, C. H.; Lindemann, H. W.; Berdel, W. E.; Staib, P.; Müller, M. C.; Proetel, U.; Balleisen, L.; Goebeler, M. E.; Dengler, J.; Falge, C.; Kanz, L.; Burchert, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Brümmendorf, Tim H.; Edinger, M.; Hofmann, W. K.; Pfirrmann, Markus; Hasford, Joerg; Krause, S.; Hochhaus, A.; Saußele, Susanne und Hehlmann, R.
(2015):
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
In: Annals of Hematology, Bd. 94, Nr. 12: S. 2015-2024
Bonifacio, E.; Ziegler, A. G.; Klingensmith, G.; Schober, E.; Bingley, P. J.; Rottenkolber, Marietta; Theil, A.; Eugster, A.; Puff, R.; Peplow, C.; Buettner, F.; Lange, K.; Hasford, Joerg und Achenbach, P.
(2015):
Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.
In: JAMA: Journal of the American Medical Association, Bd. 313, Nr. 15: S. 1541-1549
Hoffmann, V. S.; Baccarani, M.; Hasford, Joerg; Lindörfer, Doris; Burgstaller, S.; Sertic, D.; Costeas, P.; Mayer, J.; Indrak, K.; Everaus, H.; Koskenvesa, P.; Guilhot, J.; Schubert-Fritschle, Gabriele; Castagnetti, F.; Di Raimondo, F.; Lejniece, S.; Griskevicius, L.; Thielen, N.; Sacha, T.; Hellmann, A.; Turkina, A. G.; Zaritskey, A.; Bogdanovic, A.; Sninska, Z.; Zupan, I.; Steegmann, J. L.; Simonsson, B.; Clark, R. E.; Covelli, A.; Guidi, G. und Hehlmann, R.
(2015):
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.
In: Leukemia, Bd. 29, Nr. 6: S. 1336-1343
Kalmanti, L.; Saußele, Susanne; Lauseker, Michael; Muller, M. C.; Dietz, C. T.; Heinrich, L.; Hanfstein, B.; Proetel, U.; Fabarius, A.; Krause, S. W.; Rinaldetti, S.; Dengler, J.; Falge, C.; Oppliger-Leibundgut, E.; Burchert, A.; Neubauer, A.; Kanz, L.; Stegelmann, F.; Pfreundschuh, M.; Spiekermann, Karsten; Scheid, C.; Pfirrmann, Markus; Hochhaus, A.; Hasford, Joerg und Hehlmann, R.
(2015):
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
In: Leukemia, Bd. 29, Nr. 5: S. 1123-1132
Rottenkolber, Marietta; Voogd, Eef; Dijk, Liset van; Primatesta, Paola; Becker, Claudia; Schlienger, Raymond; Groot, Mark C. H. de; Alvarez, Yolanda; Durand, Julie; Slattery, Jim; Afonso, Ana; Requena, Gema; Gil, Miguel; Alvarez, Arturo; Hesse, Ulrik; Gerlach, Roman; Hasford, Joerg; Fischer, Rainald; Klungel, Olaf H. und Schmiedl, Sven
(2015):
Time Trends of Period Prevalence Rates of Patients with Inhaled Long-Acting Beta-2-Agonists-Containing Prescriptions: A European Comparative Database Study.
In: PLOS ONE 10(2), e0117628 [PDF, 518kB]
In: PLOS ONE 10(2), e0117628 [PDF, 518kB]
Lauseker, Michael; Hanfstein, Benjamin; Haferlach, Claudia; Schnittger, Susanne; Pfirrmann, Markus; Fabarius, Alice; Schlegelberger, Brigitte; Saußele, Susanne; Dietz, Christian T.; Erben, Philipp; Hehlmann, Rüdiger; Hasford, Joerg; Hochhaus, Andreas und Müller, Martin C.
(November 2014):
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.
In: Journal of cancer research and clinical oncology, Bd. 140, Nr. 11: S. 1965-1969
Hanfstein, B.; Shlyakhto, V.; Lauseker, Michael; Hehlmann, R.; Saussele, S.; Dietz, C. T.; Erben, P.; Fabarius, A.; Proetel, U.; Schnittger, S.; Krause, S. W.; Schubert, J.; Einsele, H.; Hänel, M.; Dengler, J.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, K.; Baerlocher, G. M.; Pfirrmann, Markus; Hasford, Joerg; Hofmann, W. K.; Hochhaus, A. und Muller, M. C.
(Oktober 2014):
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
In: Leukemia, Bd. 28, Nr. 10: S. 1988-1992
Hehlmann, Rüdiger; Hasford, Joerg; Pfirrmann, Markus; Lauseker, Michael; Saußele, Susanne und Hochhaus, Andreas
(September 2014):
Reply to H. Kantarjian et al.
In: Journal of Clinical Oncology, Bd. 32, Nr. 27, 3078-3078
Pfirrmann, Markus; Saussele, S.; Hochhaus, A.; Reiter, A.; Berger, U.; Hossfeld, D. K.; Nerl, C.; Scheid, C.; Spiekermann, K.; Mayer, J.; Hellmann, A.; Lechner, K.; Falge, C.; Sayer, H. G.; Bunjes, D.; Ganser, A.; Beelen, D. W.; Baldomero, H.; Schanz, U.; Heimpel, H.; Kolb, H. J.; Hasford, Joerg; Gratwohl, A. und Hehlmann, R.
(August 2014):
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.
In: Journal of Cancer Research and Clinical Oncology, Bd. 140, Nr. 8: S. 1367-1381
Proetel, Ulrike; Pletsch, Nadine; Lauseker, Michael; Müller, Martin C.; Hanfstein, Benjamin; Krause, Stefan W.; Kalmanti, Lida; Schreiber, Annette; Heim, Dominik; Baerlocher, Gabriela M.; Hofmann, Wolf-Karsten; Lange, Elisabeth; Einsele, Hermann; Wernli, Martin; Kremers, Stephan; Schlag, Rudolf; Müller, Lothar; Hänel, Mathias; Link, Hartmut; Hertenstein, Bernd; Pfirrmann, Markus; Hochhaus, Andreas; Hasford, Joerg; Hehlmann, Rüdiger und Saußele, Susanne
(Juli 2014):
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
In: Annals of Hematology, Bd. 93, Nr. 7: S. 1167-1176
[PDF, 985kB]
Lauseker, Michael; Hasford, Joerg; Pfirrmann, Markus und Hehlmann, Rüdiger
(April 2014):
The impact of health care settings on survival time of patients with chronic myeloid leukemia.
In: Blood, Bd. 123, Nr. 16: S. 2494-2496
Neukirchen, J.; Lauseker, Michael; Blum, S.; Giagounidis, A.; Lubbert, M.; Martino, S.; Siragusa, S.; Schlenk, R. F.; Platzbecker, U.; Hofmann, W. K.; Gotze, K.; Palumbo, G. A.; Magrin, S.; Kundgen, A.; Aul, C.; Hildebrandt, B.; Hasford, Joerg; Kobbe, G.; Haas, R. und Germing, U.
(2014):
Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study.
In: Leukemia Research, Bd. 38, Nr. 1: S. 57-64
Ferrer, P.; Ballarín, E.; Sabaté, M.; Vidal, X.; Rottenkolber, Marietta; Amelio, J.; Hasford, Joerg; Schmiedl, S. und Ibáñez, L.
(2014):
Antiepileptic Drugs and Suicide: A Systematic Review of Adverse Effects.
In: Neuroepidemiology, Bd. 42, Nr. 2: S. 107-120
[PDF, 173kB]
Kalmanti, L.; Saußele, Susanne; Lauseker, Michael; Proetel, U.; Muller, M. C.; Hanfstein, B.; Schreiber, A.; Fabarius, A.; Pfirrmann, Markus; Schnittger, S.; Dengler, J.; Falge, C.; Kanz, L.; Neubauer, A.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Krause, S. W.; Heim, D.; Nerl, C.; Hossfeld, D. K.; Kolb, H. J.; Hochhaus, A.; Hasford, Joerg und Hehlmann, R.
(2014):
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
In: Annals of Hematology, Bd. 93, Nr. 1: S. 71-80
Hehlmann, R.; Müller, M. C.; Lauseker, Michael; Hanfstein, B.; Fabarius, A.; Schreiber, A.; Proetel, U.; Pletsch, N.; Pfirrmann, Markus; Haferlach, C.; Schnittger, S.; Einsele, H.; Dengler, J.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Ehninger, G.; Heim, D.; Heimpel, H.; Nerl, C.; Krause, S. W.; Hossfeld, D. K.; Kolb, H. J.; Hasford, Joerg; Saußele, Susanne und Hochhaus, A.
(2014):
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV.
In: Journal of Clinical Oncology, Bd. 32, Nr. 5: S. 415-423
Schmiedl, Sven; Fischer, Rainald; Ibáñez, Luisa; Fortuny, Joan; Klungel, Olaf H.; Reynolds, Robert; Gerlach, Roman; Tauscher, Martin; Thürmann, Petra; Hasford, Joerg und Rottenkolber, Marietta
(2014):
Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children.
In: PLOS ONE 9(9), e105110 [PDF, 399kB]
In: PLOS ONE 9(9), e105110 [PDF, 399kB]
Lauseker, Michael und Hasford, Joerg
(2014):
Remission status should not be treated as a base-line covariate – Reply to Etienne et al.
In: Haematologica, Bd. 99, Nr. 9, e174-e175
Hasford, Joerg
(6. November 2013):
Use long acting beta 2 agonists only when asthma cannot be controlled otherwise.
In: BMJ British Medical Journal, Bd. 347
[PDF, 172kB]
Neumann, L.; Hoffmann, V. S.; Golgert, S.; Hasford, Joerg und Renteln-Kruse, W. von
(2013):
In-Hospital Fall-Risk Screening in 4,735 Geriatric Patients from the LUCAS Project.
In: Journal of Nutrition, Health & Aging, Bd. 17, Nr. 3: S. 264-269
Kuendgen, A.; Lauseker, Michael; List, A. F.; Fenaux, P.; Giagounidis, A. A.; Brandenburg, N. A.; Backstrom, J.; Glasmacher, A.; Hasford, Joerg und Germing, U.
(2013):
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
In: Leukemia, Bd. 27, Nr. 5: S. 1072-1079
Schmiedl, S.; Rottenkolber, Marietta; Szymanski, J.; Siegmund, W.; Hippius, M.; Farker, K.; Drewelow, B.; Hasford, Joerg und Thürmann, P. A.
(2013):
Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments.
In: Deutsches Ärzteblatt international, Bd. 110, Nr. 14: S. 244-252
Abbing-Karahagopian, V.; Kurz, X.; Vries, Frank de; van Staa, T. P.; Alvarez, Y.; Hesse, U.; Hasford, Joerg; van Dijk, L.; de Abajo, F. J.; Weil, J. G.; Grimaldi-Bensouda, L.; Egberts, A. C.; Reynolds, R. F. und Klungel, O. H.
(2013):
Bridging Differences in Outcomes of Pharmacoepidemiological Studies: Design and First Results of the Protect Project.
In: Current Clinical Pharmacology, Bd. 9, Nr. 2: S. 130-138
Hörbrand, Franziska; Bramlage, Peter; Fischaleck, Johann; Hasford, Joerg und Brunkhorst, Reinhard
(2013):
A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
In: European Journal of Clinical Pharmacology, Bd. 69, Nr. 4: S. 929-936
Hasford, Joerg
(2013):
New European Union regulation of clinical trials puts trial participants at risk.
In: BMJ: British Medical Journal, Bd. 346:
f665
Lauseker, Michael; Pfirrmann, Markus; Hoffmann, V. S. und Hasford, Joerg
(Mai 2012):
Comment On “Second-Generation Tyrosine Kinase Inhibitors Improve The Survival Of Patients With Chronic Myeloid Leukemia In Whom Imatinib Therapy Has Failed” Haematologica 2011;96(12):1779–82.
In: Haematologica, Bd. 97, Nr. 5, e14-e15
Pfirrmann, Markus; Ehninger, G.; Thiede, C.; Bornhäuser, M.; Kramer, M.; Röllig, C.; Hasford, Joerg und Schaich, M.
(2012):
Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
In: Lancet Oncology, Bd. 13, Nr. 2: S. 207-214
Rottenkolber, D.; Hasford, Joerg und Stausberg, Jürgen
(2012):
Costs of adverse drug events in german hospitals-a microcosting study.
In: Value in Health, Bd. 15, Nr. 6: S. 868-875
Rottenkolber, D.; Schmiedl, S.; Rottenkolber, Marietta; Thürmann, P. A. und Hasford, Joerg
(2012):
Drug-Induced Blood Consumption: The Impact of Adverse Drug Reactions on Demand for Blood Components in German Departments of Internal Medicine.
In: Basic and Clinical Pharmacology and Toxicology, Bd. 111, Nr. 4: S. 240-247
Amann, C.; Hasford, Joerg und Stausberg, Jürgen
(2012):
Stationäre Aufnahmen wegen unerwünschter Arzneimittelereignisse (UAE): Analyse der DRG-Statistik 2006.
In: Gesundheitswesen, Bd. 74, Nr. 10: S. 639-644
Büchner, T.; Schlenk, R. F.; Schaich, M.; Doehner, K.; Krahl, R.; Krauter, J.; Heil, G.; Krug, U.; Sauerland, M. C.; Heinecke, A.; Späth, Daniela; Kramer, M.; Scholl, S.; Berdel, W. E.; Hiddemann, Wolfgang; Hoelzer, D.; Hehlmann, R.; Hasford, Joerg; Hoffmann, V. S.; Doehner, H.; Ehninger, G.; Ganser, A.; Niederwieser, D. W. und Pfirrmann, Markus
(2012):
Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm‐Combined Prospective Analysis by the German AML Intergroup.
In: Journal of Clinical Oncology, Bd. 30, Nr. 29: S. 3604-3610
Hoffmann, Verena; Baccarani, M.; Hasford, Joerg; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus und Hehlmann, R.
(2012):
The EUTOS CML score aims to support clinical decision-making.
In: Blood, Bd. 119, Nr. 12: S. 2966-2967
Germing, U.; Lauseker, Michael; Hildebrandt, B.; Symeonidis, A.; Cermak, J.; Fenaux, P.; Kelaidi, C.; Pfeilstöcker, M.; Nösslinger, T.; Sekeres, M.; Maciejewski, J.; Haase, D.; Schanz, J.; Seymour, J.; Kenealy, M.; Weide, R.; Lübbert, M.; Platzbecker, U.; Valent, P.; Götze, K.; Stauder, R.; Blum, S.; Kreuzer, K. A.; Schlenk, R.; Ganser, A.; Hofmann, W. K.; Aul, C.; Krieger, O.; Kundgen, A.; Haas, R.; Hasford, Joerg und Giagounidis, A.
(2012):
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study.
In: Leukemia, Bd. 26, Nr. 6: S. 1286-1292
Hanfstein, B.; Müller, M. C.; Hehlmann, R.; Erben, P.; Lauseker, Michael; Fabarius, A.; Schnittger, S.; Haferlach, C.; Göhring, G.; Proetel, U.; Kolb, H. J.; Krause, S. W.; Hofmann, W. K.; Schubert, J.; Einsele, H.; Dengler, J.; Hänel, M.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Branford, S.; Hughes, T. P.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Pfirrmann, Markus; Hasford, Joerg; Saußele, Susanne und Hochhaus, A.
(2012):
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
In: Leukemia, Bd. 26, Nr. 9: S. 2096-2102
Hansson, M. G.; Simonsson, B.; Feltelius, N.; Forsberg, J. S. und Hasford, Joerg
(2012):
Medical registries represent vital patient interests and should not be dismantled by stricter regulation.
In: Cancer Epidemiology, Bd. 36, Nr. 6: S. 575-578
Stausberg, Jürgen und Hasford, Joerg
(2011):
Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data.
In: BMC Health Services Research
11:134
[PDF, 250kB]
Pfirrmann, Markus; Hochhaus, A.; Lauseker, Michael; Saußele, Susanne; Hehlmann, R. und Hasford, Joerg
(2011):
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.
In: Leukemia, Bd. 25, Nr. 9: S. 1433-1438
Stausberg, Jürgen und Hasford, Joerg
(2011):
Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data.
In: BMC Health Services Research, Bd. 11: S. 134
Rottenkolber, D.; Schmiedl, S.; Rottenkolber, Marietta; Farker, K.; Salje, K.; Mueller, S.; Hippius, M.; Thürmann, P. A. und Hasford, Joerg
(2011):
Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations.
In: Pharmacoepidemiology and Drug Safety, Bd. 20, Nr. 6: S. 626-634
Renteln-Kruse, W. von; Dapp, U.; Anders, J.; Profener, F.; Schmidt, S.; Deneke, C.; Fertmann, R.; Hasford, Joerg und Minder, C.
(2011):
The LUCAS* consortium: Objectives of interdisciplinary research on selected aspects of ageing and health care for older people in an urban community.
In: Zeitschrift für Gerontologie und Geriatrie, Bd. 44, Nr. 4: S. 250-255
Dapp, U.; Fertmann, R.; Anders, J.; Schmidt, S.; Profener, F.; Deneke, C.; Minder, C.; Hasford, Joerg und Renteln-Kruse, W. von
(2011):
Die Longitudinal-Urban-Cohort-Ageing-Studie (LUCAS).
In: Zeitschrift für Gerontologie und Geriatrie, Bd. 44, Nr. Suppl 2: S. 55-72
Fabarius, A.; Leitner, A.; Hochhaus, A.; Müller, M. C.; Hanfstein, B.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Jotterand, M.; Reiter, A.; Jung-Munkwitz, S.; Proetel, U.; Schwaab, J.; Hofmann, W. K.; Schubert, J.; Einsele, H.; Ho, A. D.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Lauseker, Michael; Pfirrmann, Markus; Hasford, Joerg; Saußele, Susanne und Hehlmann, R.
(2011):
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV.
In: Blood, Bd. 118, Nr. 26: S. 6760-6768
Hehlmann, R.; Grimwade, D.; Simonsson, B.; Apperley, J.; Baccarani, M.; Barbui, T.; Barosi, G.; Bassan, R.; Béné, M. C.; Berger, Ursula; Büchner, T.; Burnett, A.; Cross, N. C.; de Witte, T. J.; Dohner, H.; Dombret, H.; Einsele, H.; Engelich, G.; Foa, R.; Fonatsch, C.; Gökbuget, Nicola; Gluckman, E.; Gratwohl, A.; Guilhot, F.; Haferlach, C.; Haferlach, T.; Hallek, M.; Hasford, Joerg; Hochhaus, A.; Hoelzer, D.; Kiladjian, J. J.; Labar, B.; Ljungman, P.; Mansmann, Ulrich; Niederwieser, D. W.; Ossenkoppele, G.; Ribera, J. M.; Rieder, H.; Serve, H.; Schrotz-King, P.; Sanz, M. A. und Saußele, Susanne
(2011):
The European LeukemiaNet: achievements and perspectives.
In: Haematologica, Bd. 96, Nr. 1: S. 156-162
Hehlmann, R.; Lauseker, Michael; Jung-Munkwitz, S.; Leitner, A.; Müller, M. C.; Pletsch, N.; Proetel, U.; Haferlach, C.; Schlegelberger, B.; Balleisen, L.; Hänel, M.; Pfirrmann, Markus; Krause, S. W.; Nerl, C.; Pralle, H.; Gratwohl, A.; Hossfeld, D. K.; Hasford, Joerg; Hochhaus, A. und Saußele, Susanne
(2011):
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia.
In: Journal of Clinical Oncology, Bd. 29, Nr. 12: S. 1634-1642
Hasford, Joerg; Baccarani, M.; Hoffmann, Verena; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus und Hehlmann, R.
(2011):
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
In: Blood, Bd. 118, Nr. 3: S. 686-692
Hasford, Joerg; Bramlage, Peter; Koch, G.; Lehmacher, W.; Einhäupl, K. und Rothwell, P. M.
(2011):
Standards for subgroup analyses are needed?‐we couldn’t agree more.
In: Journal of Clinical Epidemiology, Bd. 64, Nr. 4, 451; author reply 452
Stausberg, Jürgen und Hasford, Joerg
(2010):
Identification of adverse drug events: The use of ICD-10 coded diagnoses in routine hospital data.
In: Deutsches Ärzteblatt international, Bd. 107, Nr. 3: S. 23-29
Saußele, Susanne; Lauseker, Michael; Gratwohl, A.; Beelen, D. W.; Bunjes, D.; Schwerdtfeger, R.; Kolb, H. J.; Ho, A. D.; Falge, C.; Holler, E.; Schlimok, G.; Zander, A. R.; Arnold, R.; Kanz, L.; Dengler, R.; Haferlach, C.; Schlegelberger, B.; Pfirrmann, Markus; Müller, M. C.; Schnittger, S.; Leitner, A.; Pletsch, N.; Hochhaus, A.; Hasford, Joerg und Hehlmann, R.
(2010):
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
In: Blood, Bd. 115, Nr. 10: S. 1880-1885
Hasford, Joerg; Uricher, J.; Tauscher, M.; Bramlage, Peter und Virchow, J. C.
(2010):
Persistence with asthma treatment is low in Germany especially for controller medication - a population based study of 483.051 patients.
In: Allergy, Bd. 65, Nr. 3: S. 347-354
Hasford, Joerg; Bramlage, Peter; Koch, G.; Lehmacher, W.; Einhäupl, K. und Rothwell, P. M.
(2010):
Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed.
In: Journal of Clinical Epidemiology, Bd. 63, Nr. 12: S. 1298-1304
Hasford, Joerg und Lehmacher, W.
(2010):
Benefit assessment in Germany.
In: New England Journal of Medicine / NEJM, Bd. 362, Nr. 4, e11; author reply e11
Bramlage, Peter und Hasford, Joerg
(2009):
Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment - a review.
In: Cardiovascular Diabetology
8:18
[PDF, 793kB]
Rohrbacher, M.; Berger, Ursula; Hochhaus, A.; Metzgeroth, G.; Adam, K.; Lahaye, T.; Saußele, Susanne; Muller, M. C.; Hasford, Joerg; Heimpel, H. und Hehlmann, R.
(2009):
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.
In: Leukemia, Bd. 23, Nr. 3: S. 602-604
Schmiedl, S.; Rottenkolber, Marietta; Szymanski, J.; Hasford, Joerg und Thürmann, P. A.
(2009):
Declining public health burden of digoxin toxicity: decreased use or safer prescribing?
In: Clinical Pharmacology & Therapeutics, Bd. 85, Nr. 2, 143-4; author reply 144
Glaeske, G.; Augustin, M.; Abholz, H.; Banik, N.; Brüggenjürgen, B.; Hasford, Joerg; Hoffmann, W.; Kruse, J.; Lange, S.; Schäfer, T.; Schubert, I.; Trampisch, H. J. und Windeler, J.
(2009):
Epidemiologische Methoden für die Versorgungsforschung.
In: Gesundheitswesen, Bd. 71, Nr. 10: S. 685-693
Messerer, D.; Engel, Jutta; Hasford, Joerg; Schaich, M.; Ehninger, G.; Sauerland, C.; Büchner, T.; Schumacher, A.; Krahl, R.; Niederwieser, D. W.; Krauter, J.; Ganser, A.; Creutzig, U.; Doehner, H. und Schlenk, R. F.
(2008):
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
In: Haematologica, Bd. 93, Nr. 6: S. 826-833
Markl, G. E.; Strunz-Lehner, C.; Egen-Lappe, V.; Lack, N. und Hasford, Joerg
(2008):
The association of psychosocial factors with nausea and vomiting during pregnancy.
In: Journal of Psychosomatic Obstetrics & Gynecology, Bd. 29, Nr. 1: S. 17-22
Waller, Patrick; Beard, Keith; Egberts, Toine; Evans, Stephen; Hallas, Jesper; Hasford, Joerg; Laporte, Joan-Ramon; Moore, Nicholas; Shakir, Saad und Sturkenboom, Miriam
(2008):
European commission consultation on pharmacovigilance.
In: Pharmacoepidemiology and Drug Safety, Bd. 17, Nr. 2: S. 108-109
Hoster, Eva; Dreyling, Martin; Klapper, Wolfram; Gisselbrecht, C.; van Hoof, A.; Kluin-Nelemans, H. C.; Pfreundschuh, M.; Reiser, M.; Metzner, B.; Einsele, H.; Peter, N.; Jung, W.; Wörmann, Bernhard; Ludwig, W. D.; Dührsen, U.; Eimermacher, H.; Wandt, H.; Hasford, Joerg; Hiddemann, Wolfgang und Unterhalt, Michael
(2008):
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Erratum.
In: Blood, Bd. 111, Nr. 2: S. 558-565
Limmroth, V.; Malessa, R.; Zettl, U. K.; Koehler, J.; Japp, G.; Haller, P.; Elias, W.; Obhof, W.; Viehöver, A.; Meier, U.; Brosig, A.; Hasford, Joerg; Putzki, N.; Kalski, G. und Wernsdörfer, C.
(2007):
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
In: Journal of Neurology, Bd. 254, Nr. 1: S. 67-77
Markl, G. E.; Strunz-Lehner, C.; Egen-Lappe, V. und Hasford, Joerg
(2007):
Prescribing patterns of anti-emetic drugs during pregnancy in Germany.
In: Archives of Gynecology and Obstetrics, Bd. 275, Nr. 6: S. 461-467
Schmiedl, S.; Szymanski, J.; Rottenkolber, Marietta; Drewelow, B.; Haase, G.; Hippius, M.; Reimann, I. R.; Siegmund, W.; May, K.; Haack, S.; Hasford, Joerg und Thürmann, P. A.
(2007):
Fingerhut ein alter Hut? Eine Analyse stationärer Aufnahmen durch digitalisassoziierte unerwünschte Arzneimittelwirkungen.
In: Medizinische Klinik, Bd. 102, Nr. 8: S. 603-611
Schmiedl, S.; Szymanski, J.; Rottenkolber, Marietta; Hasford, Joerg und Thürmann, P. A.
(2007):
Age- and gender-specific incidence of hospitalisation for digoxin intoxication.
In: Drug Safety, Bd. 30, Nr. 12: S. 1171-1173
Hehlmann, R.; Berger, Ursula; Pfirrmann, Markus; Heimpel, H.; Hochhaus, A.; Hasford, Joerg; Kolb, H. J.; Lahaye, T.; Maywald, O.; Reiter, A.; Hossfeld, D. K.; Huber, C.; Löffler, H.; Pralle, H.; Queisser, W.; Tobler, A.; Nerl, C.; Solenthaler, M.; Goebeler, M. E.; Grieshammer, M.; Fischer, T.; Kremers, S.; Eimermacher, H.; Pfreundschuh, M.; Hirschmann, W. D..; Lechner, K.; Wassmann, B.; Falge, C.; Kirchner, H. H.. und Gratwohl, A.
(2007):
Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.
In: Blood, Bd. 109, Nr. 11: S. 4686-4692
Molter-Bock, E.; Hasford, Joerg und Pfundstein, T.
(2006):
Psychopharmakologische Behandlungspraxis in Münchener Altenpflegeheimen.
In: Zeitschrift für Gerontologie und Geriatrie, Bd. 39, Nr. 5: S. 336-343
Maywald, O.; Pfirrmann, Markus; Berger, Ursula; Breitscheidel, L.; Gratwohl, A.; Kolb, H. J.; Beelen, D. W.; Tobler, A.; Metzgeroth, G.; Gnad, S. U.; Hochhaus, A.; Hasford, Joerg; Hehlmann, R. und Reiter, A.
(2006):
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.
In: Leukemia, Bd. 20, Nr. 3: S. 477-484
Thürmann, P. A.; Haack, S.; Werner, U.; Szymanski, J.; Haase, G.; Drewelow, B.; Reimann, I. R.; Hippius, M.; Siegmund, W.; May, K. und Hasford, Joerg
(2006):
Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent.
In: Clinical Pharmacology & Therapeutics, Bd. 80, Nr. 5: S. 551-553
Saußele, Susanne; Adam, K.; Hochhaus, A.; Béné, M. C.; Büchner, T.; Burnett, A.; Finazzi, G.; Fonatsch, C.; Gluckman, E.; Gökbuget, Nicola; Grimwade, D. J.; Haferlach, T.; Hallek, M.; Hasford, Joerg; Hoelzer, D.; Ljungman, P.; Niederwieser, D. W.; Serve, H.; Simonsson, B.; de Witte, T. J. und Hehlmann, R.
(2006):
Klinische Forschung im „European LeukemiaNet”.
In: Deutsche Medizinische Wochenschrift - DMW, Bd. 131, Nr. 43: S. 2423-2426
Buske, C.; Hoster, Eva; Dreyling, Martin; Hasford, Joerg; Unterhalt, Michael und Hiddemann, Wolfgang
(2006):
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vinc.
In: Blood, Bd. 108, Nr. 5: S. 1504-1508
Amann, U.; Egen-Lappe, V.; Strunz-Lehner, C. und Hasford, Joerg
(2006):
Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population.
In: Pharmacoepidemiology and Drug Safety, Bd. 15, Nr. 5: S. 327-337
Kaml, M.; Weiskirchner, I.; Keller, M.; Luft, T.; Hoster, Eva; Hasford, Joerg; Young, L.; Bartlett, B.; Neuner, C.; Fischer, K. H.; Neuman, B.; Würzner, R. und Grubeck-Loebenstein, B.
(2006):
Booster vaccination in the elderly: Their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers.
In: Vaccine, Bd. 24, Nr. 47-48: S. 6808-6811
Hasford, Joerg und Virchow, J. C.
(2006):
Excess mortality in patients with asthma on long-acting beta2-agonists.
In: European Respiratory Journal, Bd. 28, Nr. 5: S. 900-902
Pfirrmann, Markus und Hasford, Joerg
(2005):
A simulation study using validated prognostic factors to assess expected long-term survival.
In: Methods of Information in Medicine, Bd. 44, Nr. 4: S. 577-583
Lenz, G.; Dreyling, Martin; Hoster, Eva; Wörmann, Bernhard; Dührsen, U.; Metzner, B.; Eimermacher, H.; Neubauer, A.; Wandt, H.; Steinhauer, H.; Martin, S.; Heidemann, E.; Aldaoud, A.; Parwaresch, R.; Hasford, Joerg; Unterhalt, Michael und Hiddemann, Wolfgang
(2005):
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
In: Journal of Clinical Oncology, Bd. 23, Nr. 23: S. 1984-1992
Dreyling, Martin; Lenz, G.; Hoster, Eva; Van-Hoof, A.; Gisselbrecht, C.; Schmits, R.; Metzner, B.; Truemper, L.; Reiser, M.; Steinhauer, H.; Boiron, J. M.; Boogaerts, M. A.; Aldaoud, A.; Silingardi, V.; Kluin-Nelemans, H. C.; Hasford, Joerg; Parwaresch, R.; Unterhalt, Michael und Hiddemann, Wolfgang
(2005):
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
In: Blood, Bd. 105, Nr. 7: S. 2677-2684
Berger, Ursula; Maywald, O.; Pfirrmann, Markus; Lahaye, T.; Hochhaus, A.; Reiter, A.; Hasford, Joerg; Heimpel, H.; Hossfeld, D. K.; Kolb, H. J.; Löffler, H.; Pralle, H.; Queisser, W.; Hehlmann, R. und Kolb, H.-J.
(2005):
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
In: Leukemia, Bd. 19, Nr. 6: S. 984-989
Heldwein, W.; Dollhopf, M.; Rösch, T.; Meining, A.; Schmidtsdorff, G.; Hasford, Joerg; Hermanek, P.; Burlefinger, R.; Birkner, B. und Schmitt, W.
(2005):
The Munich Polypectomy Study (MUPS): Prospective Analysis of Complications and Risk Factors in 4000 Colonic Snare Polypectomies.
In: Endoscopy, Bd. 37, Nr. 11: S. 1116-1122
Hasford, Joerg
(2005):
CONTRA medikamentöse Alzheimer Therapie - Die Datenlage ist unzureichend!
In: DNP - Der Neurologe und Psychiater: S. 9-11
Hasford, Joerg; Hass, J. und Firzlaff, M.
(2005):
Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone(R)). European Journal of Neurology 12:425-431.
In: European Journal of Neurology, Bd. 12, Nr. 11: S. 916-917
Hasford, Joerg; Pfirrmann, Markus und Hochhaus, A.
(2005):
How long will chronic myeloid leukemia patients treated with imatinib mesylate live?
In: Leukemia, Bd. 19, Nr. 4: S. 497-499
Hasford, Joerg; Pfirrmann, Markus; Shepherd, P.; Guilhot, J.; Hehlmann, R.; Mahon, F. X.; Kluin-Nelemans, H. C.; Ohnishi, K.; Steegmann, J. L. und Thaler, J.
(2005):
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
In: Haematologica, Bd. 90, Nr. 3: S. 335-340
Lenz, G.; Dreyling, Martin; Schiegnitz, E.; Haferlach, T.; Hasford, Joerg; Unterhalt, Michael und Hiddemann, Wolfgang
(2004):
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
In: Journal of Clinical Oncology, Bd. 22, Nr. 24: S. 4926-4933
Dirschedl, Peter; Dugas, Martin; Hasford, Joerg; Messerer Schmid, D.; Müller, T. H. und Überla, Karl
(2004):
Biometrie, Epidemiologie und zentrale Informationstechnologie im Kompetenznetz Leukämie.
In: Medizinische Welt, Die, Bd. 55, Nr. 9: S. 290-293
Egen-Lappe, V. und Hasford, Joerg
(2004):
Drug prescription in pregnancy: analysis of a large statutory sickness fund population.
In: European Journal of Clinical Pharmacology, Bd. 60, Nr. 9: S. 659-666
Buesche, G.; Freund, M.; Hehlmann, R.; Georgii, A.; Ganser, A.; Hecker, H.; Heimpel, H.; Fonatsch, C.; Heinze, B.; Pfirrmann, Markus; Holgado, S.; Schmeil, A.; Tobler, A.; Hasford, Joerg; Buhr, T. und Kreipe, H. H.
(2004):
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
In: Leukemia, Bd. 18, Nr. 9: S. 1460-1467
Büchner, T.; Dohner, H.; Ehninger, G.; Ganser, A.; Niederwieser, D. W. und Hasford, Joerg
(2004):
Cross-trial networking in AML: a step forward rather than corner cutting.
In: Leukemia Research, Bd. 28, Nr. 6: S. 649-650
Hehlmann, R.; Berger, U.; Aul, C.; Büchner, Th; Dohner, H.; Ehninger, G.; Ganser, A.; Gökbuget, Nicola; Hoelzer, D.; Überla, Karl; Gassmann, W.; Ludwig, W. D.; Rieder, H.; Kneba, M.; Hochhaus, A.; Reiter, A.; Hiddemann, W.; Ottmann, O. G.; Germing, U.; Adelhard, K.; Dugas, M.; Dirschedl, P.; Messerer, D.; Böhme, A.; Harrison-Neu, E.; Griesshammer, M.; Kienast, J.; Kolb, H. J.; Ho, A. D.; Hallek, M.; Neubauer, A.; Schlegelberger, B.; Niederwieser, D.; Heil, G.; Müller, T. und Hasford, Joerg
(2004):
The German competence network 'Acute and chronic leukemias'.
In: Leukemia, Bd. 18, Nr. 4: S. 665-669
Hasford, Joerg; Moore, Nicholas und Hoye, K.
(2004):
Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting.
In: International Journal of Clinical Pharmacology and Therapeutics, Bd. 42, Nr. 8: S. 415-422
Buesche, G.; Hehlmann, R.; Hecker, H.; Heimpel, H.; Heinze, B.; Schmeil, A.; Pfirrmann, Markus; Gomez, G.; Tobler, A.; Herrmann, H.; Kappler, M.; Hasford, Joerg; Buhr, T.; Kreipe, H. H. und Georgii, A.
(2003):
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
In: Leukemia, Bd. 17, Nr. 12: S. 2444-2453
Dugas, Martin; Messerer, D.; Hasford, Joerg; Haferlach, T.; Heinze, B.; Ludwig, W.; Rieder, H.; Schoch, R.; Schwartz, S. und Thiel, E.
(2003):
German Multicenter Study Group for Adult ALL (GMALL): recruitment in comparison to ALL incidence and its impact on study results.
In: Annals of Hematology, Bd. 82, Nr. 2: S. 83-87
Dugas, Martin; Weinzierl, S.; Pecar, A.; Endres, S. und Hasford, Joerg
(2003):
Design and implementation of a common drug information database for a university hospital.
In: Pharmacy World and Science, Bd. 25, Nr. 4: S. 156-161
Egen, V. und Hasford, Joerg
(2003):
Prevention of neural tube defects: effect of an intervention aimed at implementing the official recommendations.
In: Sozial- und Präventivmedizin, Bd. 48, Nr. 1: S. 24-32
Berger, Ursula; Engelich, G.; Maywald, O.; Pfirrmann, Markus; Hochhaus, A.; Reiter, A.; Metzgeroth, G.; Gnad, U.; Hasford, Joerg; Heinze, B.; Heimpel, H.; Hossfeld, D. K.; Kolb, H.-J.; Löffler, H.; Pralle, H.; Queisser, W. und Hehlmann, R.
(2003):
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
In: Leukemia, Bd. 17, Nr. 9: S. 1820-1826
Birkner, B.; Fritz, N.; Schatke, W. und Hasford, Joerg
(2003):
A prospective randomized comparison of unsedated ultrathin versus standard esophagogastroduodenoscopy in routine outpatient gastroenterology practice: does it work better through the nose?
In: Endoscopy, Bd. 35, Nr. 8: S. 647-651
Haustein, K. O.; Mulzer, K. und Hasford, Joerg
(2003):
Selbstmedikation mit Nikotinpräparaten: Drei von zehn Rauchern entsagen dem blauen Dunst.
In: MMW - Fortschritte der Medizin, Bd. 145, Nr. 43: S. 46
Hehlmann, R.; Berger, Ursula; Pfirrmann, Markus; Hochhaus, A.; Metzgeroth, G.; Maywald, O.; Hasford, Joerg; Reiter, A.; Hossfeld, D. K.; Kolb, H. J.; Löffler, H.; Pralle, H.; Queisser, W.; Griesshammer, M.; Nerl, C.; Kuse, R.; Tobler, A.; Eimermacher, H.; Tichelli, A.; Aul, C.; Wilhelm, M.; Fischer, J. T.; Perker, M.; Scheid, C.; Schenk, M.; Weiss, J.; Meier, C. R.; Kremers, S.; Labedzki, L.; Schmeiser, T.; Lohrmann, H. P.; Heimpel, H.; Kolb, H.-J. und Lohrmann, H.-P.
(2003):
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
In: Leukemia, Bd. 17, Nr. 8: S. 1529-1537
Hasford, Joerg; Fagerstrom, K. O. und Haustein, K. O.
(2003):
A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation.
In: European Journal of Clinical Pharmacology, Bd. 59, Nr. 5-6: S. 443-447
Hasford, Joerg; Pfirrmann, Markus; Hehlmann, R.; Baccarani, M.; Guilhot, F.; Mahon, F. X.; Kluin-Nelemans, H. C.; Ohnishi, K.; Thaler, J. und Steegmann, J. L.
(2003):
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.
In: Seminars in Hematology, Bd. 40, Nr. 1: S. 4-12
Pfirrmann, Markus und Hasford, Joerg
(Juli 2001):
Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Comments.
In: British Journal of Haematology, Bd. 114, Nr. 1: S. 241-243
Hehlmann, Rüdiger; Hochhaus, Andreas; Kolb, Hans-Jochem; Hasford, Joerg; Gratwohl, Alois; Heimpel, Hermann; Siegert, Wolfgang; Finke, Jürgen; Ehninger, Gerhard; Holler, Ernst; Berger, Ute; Pfirrmann, Markus; Muth, Alexander; Zander, Alex; Fauser, Axel A.; Heyll, Axel; Nerl, Christoph; Hossfeld, Dieter K.; Löffler, Helmut; Pralle, Hans; Queißer, Wolfgang und Tobler, Andreas
(1. Dezember 1999):
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
In: Blood, Bd. 94, Nr. 11, 10572078: S. 3668-3677
Hasford, Joerg; Pfirrmann, Markus; Hehlmann, R.; Allan, N. C.; Baccarani, M.; Kluin-Nelemans, J. C.; Alimena, G.; Steegmann, J. L. und Ansari, H.
(3. Juni 1998):
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
In: Journal of the National Cancer Institute, Bd. 90, Nr. 11: S. 850-859
Hasford, Joerg; Ansari, H.; Pfirrmann, Markus und Hehlmann, Rüdiger
(Mai 1996):
Analysis and validation of prognostic factors for CML.
In: Bone Marrow Transplantation, Bd. 17, Nr. Supplement 3, 8769702: S. 49-54
Konferenzbeitrag
Lindörfer, Doris; Hoffmann, Verena S.; Rosti, Gianantonio; Castagnetti, Fausto; Saussele, Susanne; Guilhot, Joelle; Simonsson, Bengt; Steegmann, Juan Luis; Mayer, Jiri; Indrak, Karel; Turkina, Anna G; Zaritskey, Andrey; Labar, Boris; Zupan, Irena P; Thielen, Noortje; Clark, Richard E; Thaler, Josef; Melanthiou, Frederiki; Everaus, Hele; Porkka, Kimmo; Bogdanovic, Andrija; Schubert-Fritschle, Gabriele; Panagiotidis, Panagiotis; Masszi, Tamas; Lejniece, Sandra; Griskevicius, Laimonas; Hellmann, Andrzej; Prejzner, Witold; Sacha, Tomasz; Almeida, Antonio; Dyagil, Iryna; Colita, Adriana; Mihaylov, Georgi; Hehlmann, Rüdiger; Hasford, Joerg und Baccarani, Michele
(Juni 2014):
The EUTOS population-based registry: evaluation of baseline characteristics and first treatment choices of 2983 newly diagnosed chronic myeloid leukemia (CML) patients from 20 European countries.
19th Congress of the European Hematology Association (EHA), Mailand, Italien, 12. – 15. Juni 2014.
Haematologica.
Bd. 99, Nr. Suppl. 1
Ferrata Storti Foundation.